Aarti Drugs Q1 Profit Up 16%

  Published 8 months ago

Aarti Drugs posts 16.2% YoY PBT growth in Q1 FY26; focuses on capacity expansion, backward integration, and regulated markets.

  • EBITDA rose 12% to ₹74.4 crore; margins expanded to 12.6% as specialty, formulations, and API revenue segments grew.
  • Capex of ₹48.5 crore focused on the new Sayakha plant for anti-diabetics and the upcoming Salicylic Acid plant at Tarapur.
  • USFDA approvals, global tariff shifts create export opportunities as the company eyes a stronger presence in regulated markets.

You might like these

Prucalopride vs. Motegrity: CIC Market Insights

RBI Drafts Novation Rules for OTC

IOC Buys 7M Barrels Amid Russia Pause

Mexico Inflation Rises, Rate Cuts in Doubt

Jindal Saw Expands in UAE & Saudi Arabia with New Pipe Plants

Sensex, Nifty Mark Six-Week Losing Streak

Rupee Hits Record Low Ahead of RBI Policy

News that matters the most ⚡